MOTS-c: A Mitochondrial-Derived Peptide Research Overview

MOTS-c — “Mitochondrial Open Reading frame of the Twelve S rRNA type-c” — is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene. It is one of the most-studied members of the mitochondrial-derived peptide (MDP) class, a group of short peptides translated from small open reading frames within mitochondrial DNA. For researchers investigating mitochondrial-nuclear retrograde signaling, metabolic homeostasis, and AMPK pathway biology, MOTS-c is the prototype MDP research tool.

MOTS-c is supplied for in vitro and animal-research applications only. Nothing in this article should be read as a recommendation for human use or as a therapeutic claim.

Reference identifiers

CAS Registry Number: 1627580-64-6
Molecular formula: C₇₈H₁₃₂N₂₂O₂₂S₂
Molecular weight: ~1771 g/mol
Sequence (16 aa): Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg
Form supplied: Lyophilized white powder

The CoA should report HPLC purity ≥99.0% with chromatogram, mass spec [M+H]⁺ confirmation at ~1772, and net peptide content. The presence of two methionine residues makes oxidation a relevant CoA consideration — mass shifts of +16 or +32 Da indicate methionine sulfoxide formation.

Discovery and biology

MOTS-c was first characterized by Lee, Cohen, and colleagues at the USC Davis School of Gerontology in 2015 [Lee C et al., 2015, Cell Metabolism 21:443–454, DOI 10.1016/j.cmet.2015.02.009]. The discovery emerged from systematic interrogation of small open reading frames in the mitochondrial genome — a region historically considered to encode only the 13 canonical respiratory-chain protein subunits, the two ribosomal RNAs, and the 22 transfer RNAs. The identification of MOTS-c (and other MDPs including humanin and the SHLP series) reframed mitochondrial DNA as a source of bioactive peptides with systemic signaling roles.

The peptide is translated from a 51-nucleotide open reading frame within the mitochondrial 12S rRNA gene using mitochondrial-specific translation machinery, then exported to the cytoplasm. Plasma levels of endogenous MOTS-c have been measured in animal-model and observational human studies and reported to decline with age — a finding that motivated subsequent investigation into MOTS-c as a candidate longevity-axis signaling molecule.

Mechanism — AMPK and the folate cycle

The leading mechanistic hypothesis positions MOTS-c as an activator of AMP-activated protein kinase (AMPK), the master cellular energy sensor that couples metabolic stress to catabolic adaptation. The proposed upstream mechanism involves modulation of the methionine-folate cycle, with MOTS-c shifting folate-mediated one-carbon metabolism in a manner that elevates AICAR and consequently activates AMPK [Lee C et al., 2015 as above; Reynolds JC et al., 2021, Nature Communications, DOI 10.1038/s41467-020-20790-0].

Downstream of AMPK activation, the published preclinical literature reports:

– Increased glucose uptake in skeletal muscle of treated animals

– Improved insulin sensitivity in DIO and aged mouse models

– Translocation of MOTS-c to the nucleus under metabolic stress, where it has been reported to regulate adaptive nuclear gene expression

– Effects on adipose tissue lipolysis and thermogenic gene expression

The nuclear translocation finding is mechanistically distinctive. Unlike most peptide signaling molecules, MOTS-c has been reported to act as a retrograde signal from the mitochondria to the nucleus, with reported nuclear binding to specific chromatin loci under stress conditions [Kim KH et al., 2018, Cell Metabolism 28:516–524, DOI 10.1016/j.cmet.2018.06.008].

Preclinical animal-study findings

The published animal-study literature has investigated MOTS-c in:

Aged mouse models — reported improvements in skeletal muscle function, glucose tolerance, and metabolic flexibility under sustained MOTS-c administration
Diet-induced obesity models — reduced body weight, improved insulin sensitivity, and reduced hepatic steatosis
Exercise-physiology models — increased endurance capacity in aged animals receiving MOTS-c, with effect sizes that motivated subsequent investigation
Type 2 diabetes models — improved glycemic control in db/db and high-fat-fed rodent models

The reproducibility of these findings has been examined across multiple independent labs, though MOTS-c remains a relatively young research compound and the overall literature footprint is smaller than for mature metabolic peptides.

Pharmacokinetic considerations

MOTS-c has a short circulating half-life in unmodified form, with reported animal-study clearance in the tens of minutes range. Most published preclinical work has used sustained or repeated administration to maintain functional exposure. Engineered long-acting MOTS-c analogs are under active development but are not the standard research-grade material.

CoA verification

For a research-grade MOTS-c lot, the CoA should document:

– HPLC purity ≥99.0% with chromatogram

– Mass spectrum confirming [M+H]⁺ at ~1772 within ±0.5 Da

– Methionine oxidation status — methionine sulfoxide content is informative for a peptide with two Met residues

– Net peptide content with counterion identified

– Lot number matching the vial

The two-methionine sequence makes oxidation a real concern for long-term stability. CoAs that document oxidation-product percentage are more informative than those that omit it.

Storage

MOTS-c is supplied lyophilized. Pre-reconstitution: 2–8°C dry, dark; -20°C for archival storage. Post-reconstitution: 2–8°C in standard multi-dose diluent, use within ~28 days. The methionine residues introduce oxidative-degradation susceptibility — exclude air during reconstitution (no shaking) and minimize repeated vial entries for multi-dose preparations.

Relationship to other mitochondrial-derived peptides

MOTS-c sits in the broader MDP class alongside humanin and the SHLP (small humanin-like peptide) series. Each MDP is encoded by a different mitochondrial small ORF and engages a different downstream signaling pathway. For researchers interested in mitochondrial-protective peptide research beyond MOTS-c, the SS-31 (Szeto-Schiller) class is a structurally unrelated but mechanistically adjacent research category — though SS-31 is a synthetic mitochondria-targeted tetrapeptide rather than an MDP.

Summary

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by an open reading frame in the mitochondrial 12S rRNA gene. It activates AMPK signaling through modulation of folate-cycle one-carbon metabolism, and has been reported in animal studies to improve glucose tolerance, insulin sensitivity, and metabolic flexibility, with particular activity in aged-animal and DIO models. It is the prototype MDP research compound and serves as a tool for investigating mitochondrial-nuclear retrograde signaling.

Research Use Only. Not for use in or on humans or animals. Not a food, drug, cosmetic, or supplement.